...
首页> 外文期刊>Cancer gene therapy >Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma
【24h】

Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma

机译:RGD纤维突变腺病毒载体的转录靶向可提高自杀基因治疗鼠黑色素瘤的安全性

获取原文

摘要

Since RGD fiber-mutant adenovirus vector (AdRGD), which contains an v-integrin tropism, is highly efficient in gene transduction to melanoma, the AdRGD-mediated herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) system is an attractive approach for melanoma treatment. However, the intratumoral injection of AdRGD causes limited transgene expression in healthy normal tissue, due to unwanted vector spread. Herein, we describe our attempt to overcome this limitation related to the safety of HSVtk/GCV treatment by using AdRGD carrying either melanoma-specific tyrosinase (Tyr) promoter or tumor-specific telomerase reverse transcriptase (TERT) promoter instead of universal cytomegalovirus promoter. Our in vitro study revealed that Tyr promoter-regulated AdRGD exhibited high transgene expression specificity for melanoma cells, and that TERT promoter-regulated AdRGD could induce efficient gene expression in tumor cells, but was relatively quiescent in normal cells. Anti-B16BL6 melanoma effects in mice injected intratumorally with AdRGD-Tyr/HSVtk or AdRGD-TERT/HSVtk, after which GCV was injected intraperitoneally for 10 days, were comparable to those in mice injected with AdRGD-CMV/HSVtk at 10 times less vector dosage. On the other hand, AdRGD-Tyr/HSVtk and AdRGD-TERT/HSVtk did not induce severe adverse effects even when they were intravenously injected into mice at 109 plaque-forming units (PFU), whereas mice injected with AdRGD-CMV/HSVtk at 108PFU exhibited body weight reduction and serum level increase of biochemical enzymes for hepatotoxicity. These results indicate that AdRGD combined with transcriptional regulation using Tyr or TERT promoter is a potentially useful and safe vector system for suicide gene therapy for melanoma.
机译:由于包含v-整联蛋白嗜性的RGD纤维突变腺病毒载体(AdRGD)在向黑素瘤的基因转导方面非常有效,因此AdRGD介导的单纯疱疹病毒胸苷激酶(HSVtk)/更昔洛韦(GCV)系统是一种有吸引力的方法用于黑色素瘤治疗。然而,由于不需要的载体扩散,肿瘤内注射AdRGD导致健康正常组织中有限的转基因表达。在这里,我们描述了我们的尝试,通过使用携带黑色素瘤特异性酪氨酸酶(Tyr)启动子或肿瘤特异性端粒酶逆转录酶(TERT)启动子而非通用巨细胞病毒启动子的AdRGD来克服与HSVtk / GCV治疗安全性相关的限制。我们的体外研究表明,Tyr启动子调节的AdRGD对黑色素瘤细胞表现出高转基因表达特异性,而TERT启动子调节的AdRGD可以在肿瘤细胞中诱导有效的基因表达,但在正常细胞中相对静止。在瘤内注射AdRGD-Tyr / HSVtk或AdRGD-TERT / HSVtk的小鼠中抗B16BL6黑色素瘤的作用,然后腹膜内注射GCV 10天,与以10倍的载体注射AdRGD-CMV / HSVtk的小鼠相比,具有抗B16BL6黑色素瘤的作用剂量。另一方面,AdRGD-Tyr / HSVtk和AdRGD-TERT / HSVtk即使以109个噬菌斑形成单位(PFU)静脉注射到小鼠中,也没有引起严重的不良反应,而在108PFU表现出体重减轻和血清生化酶水平升高的肝毒性。这些结果表明,AdRGD结合使用Tyr或TERT启动子的转录调控是用于黑色素瘤自杀基因治疗的潜在有用和安全的载体系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号